KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Current Assets Current Deferred Tax Assets Current Taxes Dividends payables Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Notes Payables Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Abbott Laboratories (ABT) Operating Leases (2019 - 2021)

Abbott Laboratories' Operating Leases history spans 2 years, with the latest figure at $902.0 million for Q4 2020.

For Q4 2020, Operating Leases rose 19.47% year-over-year to $902.0 million; the TTM value through Dec 2020 reached $902.0 million, up 19.47%, while the annual FY2020 figure was $902.0 million, 19.47% up from the prior year.
Operating Leases for Q4 2020 was $902.0 million at Abbott Laboratories, up from $755.0 million in the prior quarter.
Across five years, Operating Leases topped out at $902.0 million in Q4 2020 and bottomed at $755.0 million in Q4 2019.